<![CDATA[Current Drug Research Reviews (Volume 17 - Issue 1)]]> https://www.eurekaselect.com/journal/172 RSS Feed for Journals | BenthamScience EurekaSelect (+https://www.eurekaselect.com) 2024-11-29 <![CDATA[Current Drug Research Reviews (Volume 17 - Issue 1)]]> https://www.eurekaselect.com/journal/172 <![CDATA[Preface]]>https://www.eurekaselect.com/article/1446322024-11-29 <![CDATA[Biological Importance and Therapeutic Potential of Hispidol in Medicine: An Effective Aurone from Soybean]]>https://www.eurekaselect.com/article/1361322024-11-29 <![CDATA[A Hidden Pandemic? Abuse of Gabapentinoids: A Brief Review of Recent Studies]]>https://www.eurekaselect.com/article/1363792024-11-29Background: Gabapentin and pregabalin were developed for epilepsy and neuropathic pain. They work via voltage-gated calcium channels and are used for broad-spectrum diagnoses, e.g., epilepsy, neuropathic pain, other chronic pain syndromes, anxiety disorders, alcohol-drug withdrawal syndromes, agitation, insomnia, etc. Especially in a world dealing with the opioid crisis, gabapentinoids were considered safer alternatives to opioid analgesics.

Methods: This review aims to comprehensively search and summarize recent studies concerning the abuse of gabapentinoids published between 2021 and 2022 from various regions around the world.

Results: Studies have highlighted that a history of substance use disorder is a significant risk factor for gabapentinoid abuse. Concurrent abuse of gabapentinoids with illicit drugs can exacerbate drug-related damages. Drug screening and postmortem toxicology tests have revealed an increase in gabapentinoid consumption. In response to the abuse potential, several countries have classified gabapentinoids as controlled substances.

Conclusion: Gabapentinoids are highly abused molecules worldwide. Physicians should be aware of their abuse potential.

]]>
<![CDATA[Advancing Green Chemistry in Antiviral Therapeutics: A Comprehensive Review]]>https://www.eurekaselect.com/article/1412412024-11-29 <![CDATA[Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond]]>https://www.eurekaselect.com/article/1423072024-11-29 <![CDATA[Natriuretic Peptides in Gastrointestinal Cancer: Biomarkers and Potential Therapeutic _targets]]>https://www.eurekaselect.com/article/1359162024-11-29 <![CDATA[Clinical Similarity of Biosimilars and Reference Drugs: A Comprehensive Review and New Hope for Public Health in a New Frontier]]>https://www.eurekaselect.com/article/1358212024-11-29Background: Patents and exclusive rights on reference biologics contribute to the emergence of biosimilars. Regulatory bodies, such as the Food and Drug Administration (FDA), World Health Organization (WHO), and EMA (European Medicines Agency) for assessing clinical safety, effectiveness, and consequences between biosimilars and reference medications, have established guidelines. Since generic small molecules from reference can be easily swapped, biosimilars cannot be used interchangeably and may not always indicate interchangeability due to highly restrictive properties. It can be replaced with a reference without the healthcare provider's help under the interchangeability context.

Objective: The purpose of our study is to analyze and compare evidence-based clinical safety, therapeutic potential, and importance (outcomes) of several biosimilars with their references along with clinical uses in chronic diseases.

Methods: Through a comprehensive systemic literature review of more than 100 articles involving medicinally important drugs whose bio-similarity works optimally, safety-efficacy parameters have been analyzed. Analysis of biosimilar usage, approval, and safety-efficacy aspects are majorly focused upon herein in this review.

Results: From this systemic review, it can be stated that the majority of biosimilars are clinically and statistically equivalent to their originators. As biosimilars have good safety-efficacy aspects with lower prices, their utilization can be more encouraged, which was already done by the FDA with the establishment of a public online database entitled \"Purple Book,\" which includes all information regarding biological drugs.

Conclusion: To conclude, we suggest wide spread use of high-grade biosimilars in clinical practice, may be via changing, exchanging, or switching, with appropriate clinical monitoring and pharmacovigilance to improve patient accessibility to modern medicines, as it provides similar efficacy and safety parameters across all the accumulated clinical trials and studies.

]]>
<![CDATA[Therapeutic Management and New Upcoming Approaches for Age Related Macular Degeneration]]>https://www.eurekaselect.com/article/1347062024-11-29 <![CDATA[Role of Essential Oils and Antioxidants in the Treatment of Fibrosis]]>https://www.eurekaselect.com/article/1367092024-11-29 <![CDATA[Advancement in Opioid Abuse-deterrent Formulation Technologies and Regulatory Expectation]]>https://www.eurekaselect.com/article/1367552024-11-29 <![CDATA[Modulation of Angiotensin-II and Angiotensin 1-7 Levels Influences Cardiac Function in Myocardial Ischemia-reperfusion Injury]]>https://www.eurekaselect.com/article/1382192024-11-29 <![CDATA[Bioactive Fractions Isolated from <i>Harungana madagascariensis</i> Lam. and <i>Psorospermum aurantiacum</i> Engl. Regulate Collagen and Melanin Biosynthesis Gene Expression in UVB-irradiated Cells with Additional Anti-inflammatory Potential]]>https://www.eurekaselect.com/article/1391582024-11-29 Background: Harungana madagascariensis (HM) and Psorospermum aurantiacum (PA), used traditionally for skin care, have been reported to upregulate the expression of intracellular antioxidant genes, thereby preventing melanoma and protecting fibroblast cell lines from Ultraviolet B (UVB)-induced intracellular oxidative stress.

Aims: This investigation aimed to identify major compounds in bioactive fractions using bioassay- guided fractionation.

Methods: The anti-inflammatory effect of fractions was determined by measuring their inhibitory activity on 15-lipoxygenase and nitric oxide (NO) in lipopolysaccharide-stimulated RAW 264.7 macrophage cells. Additionally, the anti-aging efficacy of the fractions was determined by assessing the expression of markers for the aging process, i.e., expression of tyrosinase (TYR), tyrosinase-related protein-1 (TRP-1), procollagen type-1 (COL1A1), and matrix metalloproteinase- 1 (MMP-1) in UVB-induced photoaging in skin cell-lines. Furthermore, UHPLCMS- based identification of the bioactive compounds from the most prominent fraction was also carried out.

Results: Hexane fraction of HM significantly inhibited (p < 0.05) the 15-lipoxygenase (IC50 = 46.80 μg/mL) and NO production (IC50 = 66.55 μg/mL), whereas hexane fraction of PA was effective (p < 0.05) in inhibiting 15-lipoxygenase activity (IC50 = 27.55 μg/mL). Furthermore, the hexane fraction of HM and methanol fraction of PA were significantly effective (p < 0.05) in reverting the UVB-mediated altered expressions of MMP-1, TYR, TRP-1, and COL1A1. Furthermore, hexane fraction of HM revealed the presence of harunganin and betulinic acid, whereas vismion D, vismin, kenganthranol B, and bianthrone 1a were identified from the methanol fraction of PA.

Conclusion: Overall, the hexane fraction of HM and methanol fraction of PA displayed effective anti-aging activities, with additional anti-inflammatory effects.

]]>
  NODES
admin 1